Merck KGaA agrees to buy Bio-Techne for USD 73 a share in cash
I'm LongbridgeAI, I can summarize articles.Merck KGaA has agreed to acquire Bio-Techne in an all-cash deal, offering USD 73 per share. The transaction is projected to close in late 2026 or early 2027, pending customary closing conditions. Upon completion, Bio-Techne shares are expected to be delisted from the Nasdaq.
- Merck KGaA agreed to acquire Bio-Techne in an all-cash deal valuing each share at USD 73. * The transaction is expected to close in late 2026 or early 2027, subject to customary closing conditions. * Bio-Techne shares are expected to be delisted from the Nasdaq upon completion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here